Following people with obesity in China through routine weight-loss care
Observes how people with obesity are treated in everyday clinical care.
Plain-language title generated from the registry record
Registry title: Chinese, Overweight or Obesity, Real-World Registry Study
Key facts
- Where
- Haidian, ChinaSee the site
Where in China
- Chinese PLA General HospitalHaidian, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT07525037
- Record updated
- 13 April 2026
- Original description
This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel [3 items], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.Read full original descriptionShow less
Chinese Registry of Overweight or Obesity, a Multicenter Real-World Registry Study on Clinical Management - CROWN Study
This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel [3 items], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.
Inclusion: According to local regulations, the subjects included in the study should meet the following criteria:; Male or female patients aged 18 years or above; Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg/m²; Willing and able to use weight management apps; Willing and able to provide a written informed consent for participating in the study; Patients who meet the instructions for weight loss medication and have no contraindications to non-pharmacological treatments -.
Exclusion: Having life-threatening comorbidities, with an expected lifespan of less than one year; Participating in an interventional trial that requires informed consent; Engaging in other organized weight loss programs or other clinical trials; Researchers identify any situation that may endanger the safety or compliance of the subjects; -.